REMS Abuse Website: All Sizzle, No Steak?
Executive Summary
AAM President Davis contends he hasn't seen any evidence showing that reference listed drug access inquiries webpage has changed innovator behavior.
You may also be interested in...
Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline
US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.
Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline
US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.
FDA Talks Tough On Complete Response Extensions
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.